{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:35:36Z","timestamp":1774647336292,"version":"3.50.1"},"reference-count":51,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p>Tenofovir alafenamide (TAF) has shown equivalent efficacy and improved safety profiles for patients with chronic hepatitis B (CHB) compared to tenofovir disoproxil fumarate (TDF). However, limited data are available for its resistance profiles.<\/jats:p>","DOI":"10.1128\/aac.01064-18","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T10:13:41Z","timestamp":1532340821000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":51,"title":["No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection"],"prefix":"10.1128","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-8828","authenticated-orcid":false,"given":"Andrea L.","family":"Cathcart","sequence":"first","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry Lik-Yuen","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, Institute of Digestive Disease and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeru","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Marcellin","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9patologie, H\u00f4pital Beaujon, Clichy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-6688","authenticated-orcid":false,"given":"Calvin Q.","family":"Pan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, NYU Langone Medical Center, NYU School of Medicine, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Shalimar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[{"name":"Hospital Universitari Vall d'Hebron, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Cox","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bandita","family":"Parhy","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Zhou","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Martin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Chang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanjia","family":"Lin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Flaherty","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn M.","family":"Kitrinos","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Gaggar","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namiki","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61412-X"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.09.033"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00939-9"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.09.020"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.10.026"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21422"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22841"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.08.063"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26686"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12613"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00138-06"},{"key":"e_1_3_3_13_2","volume-title":"Long-term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8-year results from two phase 3 trials, abstr","author":"Marcellin P","year":"2014","unstructured":"Marcellin P, Gane EJ, Flisiak R, Trinh HN, Petersen J, Gurel S, Kaita KD, Kotzev IA, Tsai N, Flaherty JF, Schall REA, Kitrinos K, Subramanian M, McHutchison JG, George J, Janssen HL, Buti M. 2014. Long-term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8-year results from two phase 3 trials, abstr. 55th Annu Meet Am Assoc Study Liver Dis, Boston, MA."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.028"},{"key":"e_1_3_3_15_2","volume-title":"prescribing information","author":"Gilead Sciences, Inc","year":"2017","unstructured":"Gilead Sciences, Inc. 2017. Vemlidy (tenofovir alafenamide) tablets, for oral use. U.S. prescribing information. Gilead Sciences, Inc, Foster City, CA."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60616-X"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30107-8"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30024-3"},{"key":"e_1_3_3_19_2","volume-title":"Int Liver Cong 2017","author":"Agarwal K","year":"2017","unstructured":"Agarwal K, Fung S, Seto WK, Lim YS, Gane E, Janssen HLA, Sharma M, Chuang WL, Bae H, Yoon KT, Flaherty JF, Lau A, Gaggar A, Suri V, Cathcart A, Lin L, Subramanian GM, Shalimar, Furusyo N, Buti M, Chan LY. 2017. A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-positive, chronic hepatitis B: efficacy and safety results at week 96, poster FRI-153. Int Liver Cong 2017. European Association for the Study of the Liver, Amsterdam, Netherlands."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000940"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pap.0000249927.67907.eb"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.08.020"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.7296"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00239-06"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.01.027"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1022"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.12.012"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01152-15"},{"key":"e_1_3_3_29_2","volume-title":"Int Liver Cong 2017","author":"Brunetto M","year":"2017","unstructured":"Brunetto M, Lim YS, Gane E, Seto WK, Osipenko M, Ahn SH, Janssen HLA, Shukla A, Chuang WL, Trinh H, Celen MK, Flaherty JF, Lau AH, Gaggar A, Suri V, Bhardwaj N, Kim K, Subramanian GM, Pan C, Izumi N, Marcellin P, Chan HLY, Buti M. 2017. A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): efficacy and safety results at week 96, presentation. Int Liver Cong 2017. European Association for the Study of the Liver, Amsterdam, Netherlands."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp3002045"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00128-15"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12613"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.223206"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.05.024"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.024"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.008"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26277"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802878"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24318"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.027"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23246"},{"key":"e_1_3_3_42_2","volume-title":"US highlights of prescribing information","author":"ViiV Healthcare","year":"2011","unstructured":"ViiV Healthcare. 2011. Epivir (lamivudine) tablets and oral solution. US highlights of prescribing information. ViiV Healthcare, Brentford, United Kingdom."},{"key":"e_1_3_3_43_2","volume-title":"Hepsera (adefovir dipivoxil) tablets, for oral use","author":"Gilead Sciences, Inc","year":"2012","unstructured":"Gilead Sciences, Inc. 2012. Hepsera (adefovir dipivoxil) tablets, for oral use. US prescribing information. Gilead Sciences, Inc., Foster City, CA."},{"key":"e_1_3_3_44_2","volume-title":"summary of product characteristics","author":"Bristol-Myers Squibb Pharmaceutical, Ltd","year":"2014","unstructured":"Bristol-Myers Squibb Pharmaceutical, Ltd. 2014. Baraclude 0.5 mg and 1.0 mg film-coated tablets: summary of product characteristics. Bristol-Myers Squibb Pharmaceuticals, Ltd., London, United Kingdom."},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01499-06"},{"key":"e_1_3_3_46_2","volume-title":"Tenofovir (TDF) is effective in lamivudine (LAM)-resistant chronic hepatitis B patients who harbor rtA194T at baseline, poster 399","author":"Fung SK","year":"2009","unstructured":"Fung SK, Mazzulli T, Sherman M, Popovic V. 2009. Tenofovir (TDF) is effective in lamivudine (LAM)-resistant chronic hepatitis B patients who harbor rtA194T at baseline, poster 399. 60th Annu Meet Am Assoc Study Liver Dis, Boston, MA."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11100"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.21.11833-11841.2003"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12069"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-13-475"},{"key":"e_1_3_3_51_2","first-page":"1","volume-title":"Antiviral methods and protocols: methods in molecular biology","author":"Liu Y","year":"2013","unstructured":"Liu Y, Kitrinos KM. 2013. In vitro phenotyping of recombinant hepatitis B virus containing the polymerase\/reverse transcriptase gene from clinical isolates, vol 1030, p 1\u201319. In Gong EY (ed), Antiviral methods and protocols: methods in molecular biology. Humana Press, Totowa, NJ."},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2011.03.006"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01064-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01064-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:57:13Z","timestamp":1645477033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01064-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1128\/AAC.01064-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.01064-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"2018-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01064-18"}}